INOVIO PHARMACEUTICALS, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | $0 | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $10.8M | — | $14.1M | — | — | — | $13.3M |
| SG&A Expense | — | $7.8M | — | $7.9M | — | — | — | $7.9M |
| Operating Income | — | $-18.6M | — | $-21.9M | — | — | — | $-21.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-6.0M | — | $-19.7M | — | — | — | $-45.5M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.07 | — | $-0.28 | — | — | — | $-0.87 |
| EPS (Diluted) | — | $-0.07 | — | $-0.28 | — | — | — | $-0.87 |
| Shares Outstanding (Basic) | 103.4M | 81.6M | 82.3M | 69.1M | 69.1M | 69.0M | 53.6M | 52.2M |
| Shares Outstanding (Diluted) | 103.4M | 81.6M | 82.3M | 69.1M | 69.1M | 69.0M | 53.6M | 52.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |